clinical trial · NCT06862206
This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab
AstraZeneca·—·recruiting·n = 1,000
Chronic Obstructive Pulmonary Diseasebenralizumab
brief summary
The objective of this study is to collect empirical data that elucidates the clinical profile and therapeutic efficacy of benralizumab among the patients aged 12 years and above, with severe eosinophilic asthma. The study will focus on the early treatment response, treatment outcomes and the change in asthma control of benralizumab therapy in a real-world setting in China. This study will also describe the physician-reported reasons for discontinuation and switching of benralizumab therapy.
started
Jul 11, 2025
primary completion
Dec 31, 2027
completion
Dec 31, 2027
last updated
Apr 21, 2026
official title
A Multicentre, Single Arm, Non-interventional, Prospective Study to Assess Demographic Characteristics and Patient Reported Outcomes in Patients With Severe Eosinophilic Asthma Treated With Benralizumab in China
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol